Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.44 Insider Own1.20% Shs Outstand176.97M Perf Week-11.56%
Market Cap3.68B Forward P/E- EPS next Y-2.41 Insider Trans-11.16% Shs Float173.87M Perf Month1.17%
Income-425.40M PEG- EPS next Q-0.68 Inst Own- Short Float16.50% Perf Quarter1.66%
Sales120.60M P/S30.54 EPS this Y289.50% Inst Trans-0.12% Short Ratio12.78 Perf Half Y19.19%
Book/sh8.49 P/B2.45 EPS next Y5.50% ROA-20.00% Target Price27.83 Perf Year-48.67%
Cash/sh8.45 P/C2.46 EPS next 5Y-7.30% ROE-26.60% 52W Range15.64 - 41.64 Perf YTD-3.59%
Dividend- P/FCF- EPS past 5Y36.30% ROI34.90% 52W High-50.02% Beta2.81
Dividend %- Quick Ratio12.50 Sales past 5Y51.60% Gross Margin81.10% 52W Low33.10% ATR1.28
Employees618 Current Ratio12.60 Sales Q/Q5.00% Oper. Margin- RSI (14)43.85 Volatility8.61% 5.37%
OptionableYes Debt/Eq0.17 EPS Q/Q-1.20% Profit Margin- Rel Volume1.43 Prev Close20.53
ShortableYes LT Debt/Eq0.17 EarningsFeb 27 AMC Payout- Avg Volume2.25M Price20.81
Recom2.40 SMA20-6.44% SMA50-6.17% SMA200-12.92% Volume3,220,555 Change1.36%
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Feb-28-20 06:30PM  Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference PR Newswire
08:15AM  Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
04:39AM  Business as Usual for No-Moat Nektar; Bempeg's Phase Three Trials With Bristol to See 2021 Readouts Morningstar
Feb-27-20 05:35PM  Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:15PM  Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results PR Newswire
Feb-20-20 12:31PM  Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 05:00PM  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Feb-17-20 10:27AM  Lee Ainslie Buys Crown Holdings, Monster Beverage GuruFocus.com
Feb-10-20 02:56PM  Here's What We Think About Nektar Therapeutics's (NASDAQ:NKTR) CEO Pay Simply Wall St.
09:28AM  Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 05:50PM  Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-03-20 09:12AM  US STOCKS-Wall Street set to open higher after steep selloff Reuters +8.30%
08:00AM  Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications PR Newswire
Jan-29-20 03:46PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR GlobeNewswire
Jan-27-20 09:08AM  3 Biotech Stocks Nearing Support Investopedia -6.44%
Jan-24-20 07:02PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR CNW Group
Jan-23-20 11:43AM  Nektar Therapeutics Pullback May Be Short-Lived Schaeffer's Investment Research
Jan-21-20 05:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-16-20 01:37PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-15-20 04:08PM  How An FDA Committee Pulled The Rug Out From This Highflying Biotech Investor's Business Daily -15.99%
10:27AM  Nektar's Pain Drug Gets Adverse Advisory Committee Decision Zacks
10:23AM  Its opioid dissed by FDA advisors, S.F. drugmaker abandons program American City Business Journals
09:17AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB Benzinga
08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
07:30AM  Nektar Stock Plunges 15% as FDA Panel Rejects Opioid Painkiller Barrons.com
04:44AM  Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug TheStreet.com
Jan-14-20 10:47PM  Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol PR Newswire
06:27PM  Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch
10:49AM  'Unlikeable' opioid from Nektar faces FDA pain point American City Business Journals
05:00AM  Top Picks 2020- Nektar Therapeutics NKTR MoneyShow
Jan-13-20 09:14AM  Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks
Jan-10-20 04:08PM  Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing Investor's Business Daily +24.69%
02:32PM  Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders Business Wire
01:34PM  Nektar Therapeutics Options Pop as Stock Soars Schaeffer's Investment Research
08:01AM  Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer TheStreet.com
06:59AM  Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) Business Wire
Jan-07-20 09:00AM  Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-24-19 01:09PM  Why A Bidding War For Synthorx Bodes Well For This Biotech Stock Investor's Business Daily
10:10AM  Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On Zacks
Dec-19-19 12:21PM  10 Stocks That Could Be Tax-Loss Buying Opportunities Benzinga
08:59AM  5 Losing Stocks From 2019 to Rebound Next Year Zacks
Dec-17-19 09:00AM  Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. PR Newswire
Dec-10-19 07:49PM  Is Nektar Therapeutics (NKTR) A Good Stock To Buy? Insider Monkey
05:00AM  Introducing Nektar Therapeutics (NASDAQ:NKTR), A Stock That Climbed 84% In The Last Three Years Simply Wall St.
Dec-09-19 10:05AM  Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting PR Newswire +13.03%
Dec-06-19 11:31AM  Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report? Zacks
Dec-03-19 09:00AM  Nektar Appoints John Northcott as Chief Commercial Officer PR Newswire
Nov-13-19 05:30PM  Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 11:11PM  Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
09:33AM  Company News For Nov 12, 2019 Zacks
Nov-11-19 04:25PM  Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug? Investor's Business Daily
08:55AM  Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug Barrons.com
Nov-10-19 11:00AM  Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology PR Newswire
Nov-09-19 05:30PM  Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-07-19 11:13AM  Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up Zacks
Nov-06-19 06:15PM  Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:03PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019 PR Newswire
Nov-03-19 10:51AM  The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Nov-01-19 09:00AM  Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting PR Newswire +6.92%
Oct-30-19 05:00PM  Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets PR Newswire
10:34AM  Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-28-19 07:46PM  Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ? Insider Monkey +6.12%
Oct-25-19 06:00AM  With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime" MoneyShow
Oct-23-19 03:26PM  16 Stocks With The Highest Long-Term Sales Growth Rate Benzinga
Oct-18-19 03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:07AM  FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
Oct-17-19 01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE
11:18AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors NKTR GlobeNewswire
Oct-16-19 06:03PM  FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
10:11AM  NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics Business Wire
10:06AM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
09:00AM  Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma PR Newswire
Oct-15-19 08:49PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm Business Wire +8.98%
05:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
05:18PM  INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ACCESSWIRE
Oct-12-19 08:03AM  Does Nektar Therapeutics (NASDAQ:NKTR) Have A Healthy Balance Sheet? Simply Wall St.
06:50AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: VAL, NKTR and NTAP ACCESSWIRE
Oct-11-19 06:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE +5.95%
03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:05AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
06:40AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Deadlines to File Lead Plaintiff Motions Related to the Following Companies: NTAP, NKTR and VAL ACCESSWIRE
Oct-10-19 07:39PM  SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics GlobeNewswire
10:04AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
06:15AM  CLASS ACTION UPDATE: Brodsky & Smith, LLC Reminds Investors of Important Class Action Deadlines Related to the Following Companies: NTAP, NKTR and VAL ACCESSWIRE
Oct-09-19 11:19AM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines GlobeNewswire
11:10AM  Nektar's Shares Drop on Rating Downgrade by Goldman Sachs Zacks
11:05AM  ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action NKTR GlobeNewswire
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm GlobeNewswire
06:58AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: NKTR, VAL and NTAP ACCESSWIRE
Oct-08-19 04:20PM  OCTOBER 18 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE -13.34%
02:00PM  Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence' Benzinga
01:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
01:12PM  [video]Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs TheStreet.com
09:42AM  Goldman Throws in the Towel on Nektar After $14 Billion Drop Bloomberg
08:23AM  Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buy MarketWatch
06:15AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines Related to the Following Companies: VAL, NKTR and NTAP ACCESSWIRE
Oct-07-19 09:20PM  SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:28AM  NKTR CLASS ACTION DEADLINE IN 11 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics ACCESSWIRE
11:00AM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
Nektar Therapeutics develops drug candidates for cancer and autoimmune disease in the United States. The company develops ONZEALD, a topoisomerase I inhibitor that is in a Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and bempegaldesleukin (NKTR-214), a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase III to treat melanoma, renal cell carcinoma, bladder cancer, non-small cell lung cancer, and other solid tumors. It is also developing bempegaldesleukin in Phase II clinical trial for treatment of urothelial cancer and immuno-oncology, as well as in various Phase I clinical trial to treat squamous cell carcinoma of the head and neck, and metastatic castration-resistant prostate cancer; and Dapirolizumab Pegol (Anti-CD40L) to treat systemic lupus erythematosus. In addition, the company develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor 7/8 agonist that is in Phase I for solid tumors; and NKTR-255, which is Phase I studies for hematological malignancies. Its approved medicines using Nektar technology include ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; MIRCERA for anemia associated with chronic kidney disease; Macugen for age-related macular degeneration; Somavert for acromegaly; and Neulasta for neutropenia. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen).; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck KGaA; and Pfizer Inc, as well as a research collaboration with Trovagene, Inc. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 18Sale22.351,39431,156174,086Feb 20 06:39 PM
Zalevsky JonathanChief R&D OfficerFeb 18Sale22.354,774106,699327,073Feb 20 06:39 PM
Labrucherie Gil MSVP, COO & CFOFeb 18Sale22.355,938132,714253,221Feb 20 06:37 PM
ROBIN HOWARD WPresident & CEOFeb 18Sale22.358,448188,813384,871Feb 20 06:38 PM
CHESS ROBERTDirectorFeb 12Sale23.508,000188,000276,973Feb 14 07:00 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Option Exercise7.2137,500270,375212,980Feb 07 07:31 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Sale22.7837,500854,250175,480Feb 07 07:31 PM
WHITFIELD ROY ADirectorDec 18Option Exercise9.2410,00092,400198,250Dec 20 06:31 PM
Zalevsky JonathanChief R&D OfficerNov 18Sale17.973,96071,161291,697Nov 20 07:07 PM
ROBIN HOWARD WPresident & CEONov 18Sale17.9713,556243,601299,219Nov 20 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 18Sale17.972,71348,753160,441Nov 20 07:06 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale17.978,863159,268219,009Nov 20 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 13Option Exercise7.2125,000180,250252,872Nov 15 06:09 PM
Labrucherie Gil MSVP, COO & CFONov 13Sale19.7925,000494,750227,872Nov 15 06:09 PM
ROBIN HOWARD WPresident & CEOOct 17Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 17Sale17.6833,333589,327312,775Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Option Exercise7.2133,334240,338346,109Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Sale17.4833,334582,678312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Option Exercise7.2125,000180,250252,872Oct 17 06:59 PM
ROBIN HOWARD WPresident & CEOOct 15Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 15Sale16.9533,333565,085312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Sale15.8325,000395,750227,872Oct 17 06:59 PM
Ajer Jeffrey RobertDirectorSep 30Sale18.062,37542,89322,375Oct 01 07:16 PM
Lingnau LutzDirectorSep 27Sale17.843,00053,52026,700Oct 02 07:51 PM
CHESS ROBERTDirectorSep 27Sale17.994,00071,960276,973Oct 01 07:15 PM
Ajer Jeffrey RobertDirectorSep 20Sale20.242,25045,54018,250Sep 24 06:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Option Exercise7.2125,000180,250177,872Sep 18 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Sale20.5225,000513,000152,872Sep 18 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerSep 05Buy17.2815,000259,200107,668Sep 09 05:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 26Option Exercise16.3130,000489,300152,872Aug 27 05:20 PM
ROBIN HOWARD WPresident & CEOAug 23Option Exercise16.3130,000489,300312,775Aug 26 05:21 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale18.151,80932,833163,154Aug 19 07:09 PM
ROBIN HOWARD WPresident & CEOAug 16Sale18.1512,551227,801282,775Aug 19 07:08 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale18.155,06391,893122,872Aug 19 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale18.153,81969,315162,759Aug 19 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale18.153,24558,89792,668Aug 19 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Option Exercise7.2125,000180,250152,935Aug 16 08:13 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Sale17.7925,000444,750127,935Aug 16 08:13 PM
ROBIN HOWARD WPresident & CEOJul 25Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 25Sale29.6533,333988,323295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Option Exercise7.2133,334240,338328,660Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Sale32.1133,3341,070,355295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Sale32.1033,3331,069,989295,326Jul 25 08:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM